|
|
 |
|
Viewing report
|
|
|
|
Cancer: Immunotherapy Beyond Monoclonals
Bioseeker, Sep 2001
Cancer is not one single disease but can be divided into almost 200 different diseases. In the United States, overall annual costs associated with cancer currently amount to $107 billion and the worldwide anti-cancer market, valued at more than $15 billion in 1998, is projected to nearly double by 2003. Based on advances in cell and molecular biology, the number of therapeutic cancer targets in pipeline is rapidly increasing. Numerous long-standing pharma companies as well as young biotechnology firms are driving cancer research today and the future.
Our Basic Platform Report, Cancer: Immunotherapy beyond Monoclonals, provides a complete and thorough description of the current cancer vaccine market, beyond antibody-based therapies. In this 140+ page report, we provide contact data, financial information, partnership activities, and descriptives about products in the market and pipeline for 37 companies active in the cancer field. Includes totally 120 companies with interest in the field, includes 164 drugs/therapies in pipeline and 211 alliances. We also present a description and analysis of areas of development, trends, collaborations, indications, and clinical trial progress for the overall market. This makes this report a comprehensive information platform with focus on the latest developments in the field of cancer immunotherapy. Cancer: Immunotherapy beyond Monoclonals, is an excellent source of information that provides you with a solid presentation of this exciting and rapidly evolving area of therapeutics.
Companies included with extensive profiles are:
Aastrom Biosciences, Antigenics, Aphton Corp, Aquila BioPharma, Argonex, Avax Technologies, AVI BioPharma, Biochem Pharma, Biomira, Cell Genesys, Chiron, Corixa, Coulter Pharmaceuticals, CTL Immunotherapies, Cytel and Epimmune, Dendreon, GeneMax Pharmaceuticals Inc., Genzyme Corporation, Idec Pharmaceuticals, IDM (Immuno Designed Molecules), ImClone systems, Immunomedics Inc., Immune Response Corp, Immunex Corp, Intracel (Perimmune), Jenner Biotherapeutic, Nexell Therapeutics Inc, Northwest Biotherapeutics, Pharmexa A/S(M&E Biotech A/S), Progenics Pharma, Ribi Immunochem Research Inc, Select Therapeutic, Therion Biologics, Titan Pharmaceuticals, Transgene SA, Vical Inc., Viragen, Xcyte Therapies
Customers who bought this item also bought
Immunotherapy in Oncology: Gaining Momentum
Drugs of Tomorrow 2000: Prostate Cancer - Hormonals and Beyond
Analysis of Cancer Immunotherapy: The World Guide
Drug Targets for Breast Cancer
Stakeholder Opinions: Ovarian Cancer - Beyond Carboplatin and Paclitaxel
Cancer Vaccines Fantasy or Future?
25+ Business Development and Innovation Opportunities in Cancer Medicine - 2001
Drug Delivery in Cancer - Technologies, Markets and Companies
|
|
|
|
